A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 1, 2005, Pages 64-69

  Van Holten, J ^b   Pavelka, K ^c   Vencovsky, J ^c   Stahl, H ^d   Rozman, B ^e   Genovese, M ^f   Kivitz, A J ^g   Alvaro, J ^h   Nuki, G ⁱ   Furst, D E ^j   Herrero Beaumont, G ^k   McInnes, I B ^l   Musikic, P ^m   Tak, Paul P ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g Altoona Center for Clinical Research   (United States)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m Serono International SA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; COLLAGEN; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTHROSCOPY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS LINKING; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; JOINT BIOPSY; JOINT RADIOGRAPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIUM; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; METHOTREXATE; MIDDLE AGED; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 19944429963     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.020347     Document Type: Article

References (28)

1. Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995;34(suppl 2):87-90.
2. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
3. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
4. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
6. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
7. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
8. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study group. Lancet 1998;352:1498-504.
9. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis. Ann Neurol 1999;46:197-206.
10. Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997;8:345-9.
11. Smeets TJ, Dayer JM, Kraan MC, Versendaal J, Chicheportiche R, Breedveld FC, et al. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:270-4.
12. van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res 2002;4:346-52.
13. Palmer G, Mezin F, Juge-Aubry CE, Plater-Zyberk C, Gabay C, Guerne PA. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis Jan 2004;63:43-9.
14. Tak PP, Hart BA, Kraan MC, Jonker M, Smeets TJ, Breedveld FC. The effects of interferon beta treatment on arthritis. Rheumatology (Oxford) 1999;38:362-9.
15. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression or interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999;42:90-9.
16. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-beta slows cartilage destruction and reduces inflammation in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004;6:R239-49.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416:744-9.
19. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
20. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
21. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
22. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
23. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
24. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeefs TJ, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
25. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000;39:43-9.
26. Kaufmann J, Mueller A, Voigt A, Carl HD, Gursche A, Zacher J, et al. Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis. Rheumatology (Oxford) 2003;42:314-20.
27. Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 1999;26:2089-93.
28. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.